Cassady Schiller Wealth Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Cassady Schiller Wealth Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$48	Buy	+10	New	+$48	﹤0.01%	1131

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Cassady Schiller Wealth Management's VNDA Position: Q4 2024 in Review

Cassady Schiller Wealth Management opened a new position in Vanda Pharmaceuticals (VNDA) in Q4 2024: 10 shares worth $48. The stake represents ﹤0.01% of the portfolio and ranks #1131 among its holdings.

146 funds tracked by Wall St. Rank hold VNDA as of Q4 2024.

Cassady Schiller Wealth Management held 10 shares of Vanda Pharmaceuticals worth $48 as of Q4 2024.
Vanda Pharmaceuticals was a new Cassady Schiller Wealth Management position in Q4 2024.
Vanda Pharmaceuticals made up ﹤0.01% of Cassady Schiller Wealth Management's portfolio in Q4 2024, its #1131 holding.
146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.